Medtrum unveils smallest closed-loop diabetes system in China

Medtrum debuted its TouchCare AID System at the 9th China International Import Expo in Shanghai, bringing the company’s latest closed-loop diabetes platform to Mainland China for the first time. The launch matters because the system pairs smaller wearable hardware with automated insulin delivery, a step Medtrum says can make diabetes care easier to use every day.

Why it matters: - Medtrum is positioning the TouchCare AID System as a more discreet option for people managing diabetes with automated insulin delivery. - The debut adds a new closed-loop diabetes technology option to Mainland China after years of overseas commercialization. - The company says the system’s smaller size is meant to reduce friction in daily use, not just shrink the device footprint.

What happened: - Medtrum concluded its appearance at the 9th China International Import Expo, held Nov. 5-10 at the National Exhibition and Convention Center in Shanghai. - The TouchCare AID System made its Mainland China debut during the six-day exhibition. - The system combines the S10 CGM, the Nano 200U tubeless patch pump and Medtrum’s APGO® algorithm in one connected platform. - Medtrum described the combined product as the world’s smallest tubeless closed-loop AID system, based on its comparison of commercially available products as of November 2026.

The details: - The S10 CGM is described as the world’s smallest CGM. - The Nano 200U is described as the world’s smallest 200U tubeless patch pump. - The system uses a fine sensor filament placed just under the skin. - Glucose data updates every two minutes. - Medtrum’s APGO® algorithm processes glucose data and works with the pump to automatically adjust insulin delivery. - The system is designed to connect glucose sensing, algorithm-driven insulin adjustment and insulin delivery into one closed loop. - Medtrum was founded in 2008 and maintains its R&D base in Zhangjiang, Shanghai. - Zhangjiang is one of Shanghai’s major science and technology hubs. - Medtrum expanded internationally early rather than first building a domestic diabetes business and then going abroad. - The company says working across different healthcare systems helped shape its products through feedback from clinicians, users and reimbursement environments. - Medtrum products are available in more than 50 countries and regions. - The company says reimbursement coverage exists in more than 20 European countries. - Medtrum products are covered in the UK, France, Germany, Italy, the Netherlands and the Nordic countries. - The company exhibited in the Zhangjiang Incubation & Innovation Pavilion at CIIE alongside 31 companies. - More than 10 products and technologies in that pavilion made their global or China debut during the show.

Between the lines: - Medtrum is using miniaturization as a product strategy and a brand message, with the size of the devices serving as a visible differentiator at the booth. - The Shanghai debut signals that Medtrum is now bringing overseas-tested technology back into its home market. - The company’s messaging suggests it wants Chinese patients and clinicians to view the system as more mature because it has already been used in multiple healthcare settings. - The launch also shows how CIIE continues to function as a stage for first-look technology introductions in China.

What's next: - Medtrum said more updates on the TouchCare AID System and the company’s next steps in China will follow. - The company is likely to use the CIIE debut to build awareness around its closed-loop platform in the Chinese market. - Further commercial or regulatory developments were not detailed in the announcement.

The bottom line: - Medtrum used CIIE to bring its smallest closed-loop diabetes system home to Mainland China, betting that compact design plus automated insulin delivery will resonate in a growing diabetes tech market.